Needham Reiterates Buy on Sarepta Therapeutics, Maintains $235 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $235.
June 27, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics and maintained a price target of $235.
The reiteration of a Buy rating and a high price target of $235 by a reputable analyst is likely to positively impact investor sentiment and drive short-term price appreciation for Sarepta Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100